Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.259
-4.18 %
$ 2.59 M
Market Cap
-0.04
P/E
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.[ Read More ]
The intrinsic value of one PTPI stock under the base case scenario is HIDDEN Compared to the current market price of 0.259 USD, Petros Pharmaceuticals, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart PTPI
FINANCIALS
5.82 M
REVENUE
-13.6 M
OPERATING INCOME
-8.16 M
NET INCOME
-7.63 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
11.5 M
FINANCING CASH FLOW
1.58 B
REVENUE
-2.34 B
OPERATING INCOME
-5.04 B
NET INCOME
-3.57 B
OPERATING CASH FLOW
-19.1 M
INVESTING CASH FLOW
-5.85 B
FINANCING CASH FLOW
Balance Sheet Decomposition
Petros Pharmaceuticals, Inc.
| Current Assets | 20.4 M |
| Cash & Short-Term Investments | 13.3 M |
| Receivables | 2.23 M |
| Other Current Assets | 4.83 M |
| Non-Current Assets | 13.4 M |
| Long-Term Investments | 0 |
| PP&E | 255 K |
| Other Non-Current Assets | 13.2 M |
| Current Liabilities | 10.8 M |
| Accounts Payable | 1.71 M |
| Short-Term Debt | 1.28 M |
| Other Current Liabilities | 7.78 M |
| Non-Current Liabilities | 10.5 M |
| Long-Term Debt | 7 M |
| Other Non-Current Liabilities | 3.55 M |
EFFICIENCY
Earnings Waterfall
Petros Pharmaceuticals, Inc.
| Revenue | 5.82 M |
| Cost Of Revenue | 1.63 M |
| Gross Profit | 4.19 M |
| Operating Expenses | 17.8 M |
| Operating Income | -13.6 M |
| Other Expenses | -5.45 M |
| Net Income | -8.16 M |
RATIOS
71.98%
GROSS MARGIN
-233.88%
OPERATING MARGIN
-140.20%
NET MARGIN
-65.41%
ROE
-24.15%
ROA
-66.45%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Petros Pharmaceuticals, Inc.
| Net Income | -8.16 M |
| Depreciation & Amortization | 3.42 M |
| Capital Expenditures | -1 |
| Stock-Based Compensation | 417 K |
| Change in Working Capital | 625 K |
| Others | -3.33 M |
| Free Cash Flow | -7.63 M |
Wall Street Analysts Price Targets
Petros Pharmaceuticals, Inc.
PTPI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
11132.42%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Petros Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Dec 22, 2021
|
Bought 500 K USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 145773
|
3.43 USD |
|
2 years ago
Dec 22, 2021
|
Bought 383 K USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 109329
|
3.5 USD |
|
2 years ago
Nov 29, 2021
|
Bought 1.5 M USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 500000
|
3 USD |
|
2 years ago
Nov 29, 2021
|
Bought 1.31 M USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 375000
|
3.5 USD |
|
3 years ago
Oct 18, 2021
|
Bought 2.85 M USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 1661807
|
1.715 USD |
|
3 years ago
Oct 18, 2021
|
Bought 2.85 M USD
|
SHULMAN JOHN D
director, 10 percent owner: |
+ 1661807
|
1.715 USD |
7. News
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its App Technology ("App Comp"), which has unique differences from the current Drug Facts Label ("DFL"). Of the 31 objectives, 29 scored >90% comprehension Point Estimate ("PE"), 30 scored >86.7% comprehension PE, and all scored > 80% comprehension PE.
accesswire.com
- 2 months ago
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference.
accesswire.com
- 2 months ago
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA® (avanafil) for consumers. This analysis suggested support for the primary study results and demonstrated improved correct self-selection outcomes resulting from patients using the Company's proprietary Web App Technology and its embedded clinically validated diagnostic tool relative to subsequent verbal interviews that were designed into the study protocol as a form of validation of an ED diagnosis.
accesswire.com
- 3 months ago
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology, designed to assist in the appropriate consumer self-selection for receiving the drug, had a statistically significant (p
accesswire.com
- 4 months ago
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. "With Lemonaid's nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.
accesswire.com
- 6 months ago
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new collaboration with Lemonaid Health, leading telemedicine provider and a subsidiary of 23andMe, serving hundreds of thousands of patients with quality healthcare. As part of the collaboration, prescription STENDRA® (avanafil) in all strengths will be available through Lemonaid Health's telehealth platform.
accesswire.com
- 6 months ago
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received positive feedback from the U.S. Food and Drug Administration (the "FDA," or the "Agency") following the FDA's informal review of Petros' technology component for self-selection as the Company endeavors to achieve OTC status for STENDRA. The Agency acknowledged that the technology addressed some of its concerns regarding the PDE5 inhibitor class in that context, particularly with regard to nitrate-using patients.
accesswire.com
- 7 months ago
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces positive results of an initial cohort of its self-selection study comparing the use of a Drug Facts Label (DFL) alone to a DFL in combination with a web app (technology component).
accesswire.com
- 7 months ago
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has successfully launched its artificial intelligence (AI) tool developed as a result of its collaboration with a multi-billion-dollar software developer. The tool is being integrated into the Company's web app being used for patient self-screening, which it is testing in its recently launched Human Factors study.
accesswire.com
- 7 months ago
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as part of the Company's ongoing efforts to bring STENDRA over the counter. The technology will be integrated into the core tool the Company has already developed as part of its Self-Selection Study, which is currently underway.
accesswire.com
- 9 months ago
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
FDA requests meeting to review the Company's technology component and discuss further development and requirements NEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has scheduled two meetings with the U.S. Food and Drug Administration (FDA) to review the Company's progress and path forward in developing STENDRA as the first PDE-5 inhibitor approved as an over-the-counter medication for erectile dysfunction. (Please see Important Safety Information below.
accesswire.com
- 9 months ago
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status NEW YORK, NY / ACCESSWIRE / January 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the successful completion of the initial cohort of a Phase 2 equivalent Self-Selection Study (SSS).
accesswire.com
- 10 months ago
8. Profile Summary
Petros Pharmaceuticals, Inc. PTPI
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 2.59 M
Dividend Yield
11132.42%
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Contact
1185 Avenue of the Americas, New York, NY, 10036
https://www.petrospharma.com
IPO Date
Dec. 2, 2020
Employees
21
Officers
Mr. Mitchell S. Arnold M.B.A.
Vice President of Finance & Chief Accounting Officer
Mr. Fady Boctor M.B.A.
President & Chief Commercial Officer